By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
A crucial technique for identifying heart rhythm abnormalities is ECG recording. Arrhythmias that have not been picked up by a standard 12-lead ECG or 24–48-hour ECG Holter can be found by long-term monitoring.
ECG recorders are getting smaller, recording times are getting longer, and ECG monitoring facilities are getting better with time. Continuous ECG recording is currently widely accessible. Additional monitoring alternatives for patients with known or suspected arrhythmias include smart watches and fitness bracelets.
The most crucial factor in choosing the best ECG recorder and recording time is still the type and frequency of the individual’s symptoms.
Although it is far less complex and easy than a 24-hour ECG recorder, this device enables us to monitor the heart’s rhythm during uncommon or asymptomatic episodes. Implanting a loop recorder is a solution, however this is an invasive operation made for longer recording periods of three or more years.
The battery-powered device uses a regular phone connection to transfer recorded data to a website, where it is uploaded and sent to our office.
The Global long term ECG monitor market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
A few of the primary factors driving the growth of the global ECG monitors market are the sharp rise in cardiovascular mortality worldwide and the rising costs of healthcare in developed nations.
Additionally, the market is growing due to the rapidly expanding prevalence of cardiac conditions and the rising incidence of heart illnesses, particularly in the geriatric population. These factors have increased the need for continuous monitoring.
The introduction of error-free technology by market participants, together with increased investments and funding for hospitals to improve patient care, are also expected to support the overall growth. However, the market’s growth is constrained by expensive ECG monitor costs as well as a lack of consumer awareness of personal health.
Markets for ECG monitors are divided by kind and region. The market is divided into four categories based on type: event monitoring systems, holter monitoring systems, stress ECG monitoring systems, and ECG monitoring equipment. The market is split into North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa based on geography.
The TruVue Wireless Ambulatory long term ECG monitor System was developed by Biomedical Systems, a leading provider of cardiac diagnostic services and solutions, for the diagnosis and treatment of complicated cardiac arrhythmia, including atrial fibrillation.
The diagnostic advantages of TruVue include its capacity to wirelessly record and transmit each heartbeat for up to 30 days, perform sophisticated arrhythmia analysis, and offer instant online access to every sent ECG.
Electrophysiologists and cardiologists can benefit from a Holter and a cardiac event monitor in one device with TruVue. The TruVue system was created by Biomedical Systems in response to the demand from clinicians for a long-term ECG monitoring device to manage the treatment of patients with atrial fibrillation and to diagnose symptoms suggestive of cardiac arrhythmia.
The unique system makes use of cellular communication to send recordings of each pulse to the safe servers of Biomedical Systems. The algorithms of the system examine the incoming data for morphology, rate, and rhythm changes as well as patient-triggered alarms when symptoms are felt.
Based on cardiac events or notification criteria, certified cardiac technicians can warn doctors, check the results, and disseminate reports in real time. Physicians can at any time access data online, including any recorded long term ECG monitor data as well as trend reports outlining 24-hour heart rate and rhythm issues, such as atrial fibrillation.
TruVue expedites the diagnosis of patients who may have cardiac arrhythmia, including atrial fibrillation, by offering the most complete long-term image of the heart rhythm. It gives doctors the unique opportunity to review every heartbeat for up to 30 days with TruVue, combining algorithm-triggered long term ECG monitor recordings and patient-recorded episodes, and to get information online right away without going through support personnel.
Both the CE Mark for international sales and the 510(k) certification from the American Food and Drug Administration have been granted to TruVue. the Cardiology Division of Biomedical Systems has used TruVue to perform thousands of long term ECG monitor wireless telemetry treatments.
